Body Weight, Aspirin Dose and Pro-resolving Mediators
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study employs a placebo-controlled randomized cross-over design to investigate the
impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators
in blood and neutrophils.